Literature DB >> 21468523

Clinical and molecular aspects of a pediatric metachronous adrenocortical tumor.

Lorena de Oliveira Lima1, Antonio Marcondes Lerario, Guilherme Asmar Alencar, Luciana Pinto Brito, Madson Queiroz Almeida, Sorahia Domenice, Ana Claudia Latronico, Berenice Bilharinho Mendonca, Maria Candida Barrison Villares Fragoso.   

Abstract

The occurrence of metachronous adrenocortical carcinoma has rarely been described. We report a case of a child with virilizing adrenocortical metachronous tumors that, despite several metastases, presented long-term survival (15 years). We analyzed in this tumor IGF2, IGF1R and FGFR4 gene expression, and evaluated the presence of p.R337H germline p53 mutation and somatic CTNNB1 mutation. IGF2 gene was over-expressed in both left (Weiss score 5) and right (Weiss 7) adrenocortical tumors. IGF1R expression levels were higher in the right adrenocortical tumor. FGFR4 over-expression was also detected in the right adrenocortical tumor. In addition, this patient harbors the germline p.R337H p53 mutation and loss of heterozygosity (LOH) was detected in the tumors. No somatic CTNNB1 mutations were found in both tumors. In conclusion, we demonstrated in this unusual case the over-expression of growth signaling pathways, which are molecular mechanisms previously related to adrenocortical tumorigenesis. Furthermore, the absence of somatic CTNNB1 mutations, which is a molecular marker of poor prognosis in adults, might be related to the long-term survival of this patient.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21468523     DOI: 10.1590/s0004-27302011000100010

Source DB:  PubMed          Journal:  Arq Bras Endocrinol Metabol        ISSN: 0004-2730


  4 in total

Review 1.  Adrenocortical carcinoma.

Authors:  Tobias Else; Alex C Kim; Aaron Sabolch; Victoria M Raymond; Asha Kandathil; Elaine M Caoili; Shruti Jolly; Barbra S Miller; Thomas J Giordano; Gary D Hammer
Journal:  Endocr Rev       Date:  2013-12-20       Impact factor: 19.871

Review 2.  Association of adrenocortical carcinoma with familial cancer susceptibility syndromes.

Authors:  Tobias Else
Journal:  Mol Cell Endocrinol       Date:  2011-12-19       Impact factor: 4.102

3.  Common module analysis reveals prospective targets and mechanisms of pediatric adrenocortical adenoma and carcinoma.

Authors:  Anurag Kulshrestha; Shikha Suman
Journal:  Oncol Lett       Date:  2017-12-19       Impact factor: 2.967

Review 4.  What 20 years of research has taught us about the TP53 p.R337H mutation.

Authors:  Emilia Modolo Pinto; Gerard P Zambetti
Journal:  Cancer       Date:  2020-08-17       Impact factor: 6.860

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.